Contents: TRAIL (C13) Blocking Peptide
Catalog Number: 66-P737
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN3 and 100 μg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.
|
|
|
Questions? Please consult our answers to frequently asked questions at
http://www.ebioscience.com/faq.
Description
This is a peptide mapping to the carboxy terminus of human TRAIL. Several members of the growing TNF superfamily can regulate the elimination of immune cells by inducing apoptosis (1). TRAIL (TNF-related apoptosis-inducing ligand) or APO-2L is a member of the TNF superfamily that induces apoptosis by activating the death receptors DR4 and DR5 (2,3). TRAIL is attracting great interesting as an anti-cancer agent because it can induce apoptosis in a broad range of tumor cells, but only rarely in non-transformed cells, and independently of p53 status (2&4). For a time it was a it was unclear how TRAIL could induce apoptosis in tumor cells but not in non-transformed cells, while both of the cell types expressed the DR4 and DR5 death receptors. The discovery that DcR1 or TRID are mostly expressed on normal cells but not in most cancer cell lines helped to solve the puzzle, because these proteins act as decoys for the TRAIL protein (5).
Applications Reported
For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.
References
1. Pitti R. M., Marsters S.A., Siegfried R., Donahue C.J., Moore A., Ashkenazi A. 1996. Induction of Apoptosis by Apo-2 ligand, a New Member of the Tumor Necrosis Factor Cytokine Family. JBC 271(22):12687-12690.
2. Wajant H., Pfizenmaier K., Scheurich P. 2002. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7(5):449-459.
3. Phillips T.A., Ni J., Pan G., Ruben S.M., Wei Y., Pace J.L., Hunt J.S. 1999. TRAIL (Apo-2L) and TRAIL Receptors in Human Placentas: Implications for Immune Privilege. Journal of Imm 162:6053-6059.
4. 4. Nagane M., Huang H.J., Cavenee W.K. 2001. The potential of TRAIL for cancer chemotherapy. Apoptosis 6(3):191-197.
5. Gura T. 1997. How TRAIL Kills Cancer Cells, But not Normal Cells. Science 277(8):768.
Related Products
Cat. 14-6737 Purified anti-human TRAIL (CD253) polyclonal (clone Polyclonal)
